Summary by Moomoo AI
Apollomics Inc., a biopharmaceutical company incorporated in the Cayman Islands and headquartered in the United States, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on May 20, 2024. The company, which focuses on the discovery and development of oncology therapies, has registered Class A ordinary shares for resale, which may be offered by certain selling securityholders from time to time. The registration statement includes a prospectus that provides detailed information about the company, its operations, and the offered securities. Apollomics Inc. will not receive any proceeds from the sale of shares by the selling securityholders. The company has obtained an undertaking from the Financial Secretary of the Cayman Islands, guaranteeing that no tax on profits, income...Show More